Abcellera Biologics Inc
F:8QQ

Watchlist Manager
Abcellera Biologics Inc Logo
Abcellera Biologics Inc
F:8QQ
Watchlist
Price: 3.029 EUR 2.68% Market Closed
Market Cap: €890.7m

Wall Street
Price Targets

8QQ Price Targets Summary
Abcellera Biologics Inc

Wall Street analysts forecast 8QQ stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 8QQ is 8.607 EUR with a low forecast of 6.067 EUR and a high forecast of 14.416 EUR.

Lowest
Price Target
6.067 EUR
100% Upside
Average
Price Target
8.607 EUR
184% Upside
Highest
Price Target
14.416 EUR
376% Upside
Abcellera Biologics Inc Competitors:
Price Targets
TES
Tesmec SpA
39% Upside
MNPR
Monopar Therapeutics Inc
107% Upside
SCM
Solutions Capital Management SIM SpA
42% Upside

Revenue
Forecast

37% / Year
Past Growth
-22% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat
37% / Year
Past Growth
-22% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat

For the last 6 years the compound annual growth rate for Abcellera Biologics Inc's revenue is 37%. The projected CAGR for the next 3 years is -22%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-15%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-15%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is 8QQ's stock price target?
Price Target
8.607 EUR

According to Wall Street analysts, the average 1-year price target for 8QQ is 8.607 EUR with a low forecast of 6.067 EUR and a high forecast of 14.416 EUR.

What is Abcellera Biologics Inc's Revenue forecast?
Projected CAGR
-22%

For the last 6 years the compound annual growth rate for Abcellera Biologics Inc's revenue is 37%. The projected CAGR for the next 3 years is -22%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett